Received: 10 February 2021
Accepted: 7 March 2022
First Online: 29 March 2022
: This study was approved by the respective institutional review boards of the contributing sites with all participants providing written consent. This analysis was found to be exempt by the Columbia University IRB (Protocol Number AAAS6975).
: Not applicable.
: FAP is a consultant for and equity holder of Imij Technologies. SAS serves on the scientific advisory board of Meira GTX and is an equity holder in Imij Technologies. XF, FAP, and SAS have applied for a provisional patent on neuroimaging-based diagnosis.